Evidence map›Paper›PMID 37115732›Full record

ArticlePloS one2023

Time to diabetic neuropathy and its predictors among adult type 2 diabetes mellitus patients in Amhara regional state Comprehensive Specialized Hospitals, Northwest Ethiopia, 2022: A retrospective follow up study.

Sharie Tantigegn, Atsede Alle Ewunetie, Moges Agazhe, Abiot Aschale, Muluye Gebrie, Gedefaw Diress, Bekalu Endalew Alamneh

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sharie TantigegnDega Damot District Health Office, West Gojjam, Feresbet, Ethiopia.
Atsede Alle EwunetieDepartment of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Moges AgazheDepartment of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Abiot AschaleDepartment of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Muluye GebrieDepartment of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Gedefaw DiressDepartment of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Bekalu Endalew AlamnehDepartment of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID 0000-0002-5646-4379
Debre Markos University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic neuropathy is the primary cause of foot ulcers and amputations in both industrialized and poor countries. In spite of this, most epidemiological research on diabetic neuropathy in Ethiopia have only made an effort to estimate prevalence, and the information underlying the condition's beginning is not well-established. Therefore, determining the time to diabetic neuropathy and its variables among adult patients with type 2 diabetes mellitus at the Compressive Specialized Hospitals of the Amhara region was the aim of this study.

methodsAn institutional-based retrospective follow-up study was undertaken among 669 newly recruited adult patients with type 2 diabetes mellitus who were diagnosed between the first of March 2007 and the last day of February 2012. Patients with diabetic neuropathy at the time of the diagnosis for type 2 diabetes mellitus (T2DM), patients without a medical chart, patients with an unknown date of DM diagnosis, and patients with an unknown date of diabetic neuropathy diagnosis were excluded from the study. All newly diagnosed type 2 diabetes mellitus (T2DM) patients aged 18 years and older who were enrolled from 1st March 2007 to 28th February 2012 in selected hospitals were included in this study. Cox proportional hazard model was fitted to determine predictors of time to diabetic neuropathy, and the Kaplan Meier survival curve was used to assess the cumulative survival time. Variables with a p-value < 0.05 were considered to be statistically significance at 95% confidence interval.

resultsThe restricted mean survival time of this study was 179.45 (95% CI: 173.77-185.14) months. The overall incidence rate of diabetic neuropathy was 2.14 cases per 100 persons-years. Being aged > 60 years [AHR = 2.93(95% CI: 1.29-6.66)], having diabetic retinopathy [AHR = 2.76(95% CI: 1.84-4.16)], having anemia [AHR = 3.62 (95% CI: 2.46-5.33)], having hypertension [AHR = 3.22(95% CI: 2.10-4.93)], and baseline fasting blood sugar > 200 mg/dl [AHR = 2.56(95% CI: 1.68-3.92)] were the predictors of diabetic neuropathy.

conclusionThe risk of occurrence of diabetic neuropathy among type two diabetes mellitus patients was high in the early period. Age > 60 years, diabetic retinopathy, anemia, baseline fasting blood sugar level > 200 mg/dl, and hypertension were the main predictors of incidence of diabetic neuropathy. Therefore, early detection and appropriate interventions are important for patients with old age, diabetic retinopathy, anemia, hypertension, and FBS > 200mg/dl.

Indexed as

Diabetes Mellitus, Type 2Diabetic NeuropathiesDiabetic RetinopathyHypertensionAdultBlood GlucoseEthiopiaFollow-Up StudiesHospitalsHumansRetrospective StudiesRisk FactorsBlood Glucose

Identifiers

PMID37115732
PMCPMC10146479
OpenAlexW4367309489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.